{"id":390537,"date":"2018-11-30T00:00:00","date_gmt":"2018-11-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfhe0001-2018-biopharma-hemophilia-disease-landscape-and-forecast-hemophilia-a-g7-2018\/"},"modified":"2026-03-31T10:47:41","modified_gmt":"2026-03-31T10:47:41","slug":"dlsfhe0001-2018-biopharma-hemophilia-disease-landscape-and-forecast-hemophilia-a-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfhe0001-2018-biopharma-hemophilia-disease-landscape-and-forecast-hemophilia-a-g7-2018\/","title":{"rendered":"Hemophilia | Disease Landscape and Forecast | Hemophilia A | G7 | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p><abbr data-original-title=\"Decision Resources Group\" title=\"\">DRG<\/abbr>\u00a0anticipates the next ten years to be an exciting time in the hemophilia A space as the number of treatment options grow for patients with, and without, inhibitors. The hemophilia A pipeline is diverse, both in terms of technology type and administration route, and we are witnessing a shift in\u00a0<abbr data-original-title=\"research and development\" title=\"\">R&#038;D<\/abbr>\u00a0emphasis; there is growing interest in nonfactor treatment approaches to restore coagulation. Examples include the launch of Roche\/Chugai\u2019s bispecific antibody Hemlibra, and the development of gene therapies, such as BioMarin\u2019s BMN 270, and the anti-<abbr data-original-title=\"tissue factor pathway inhibitor\" title=\"\">TFPI<\/abbr>\u00a0drug class, with agents like Novo Nordisk\u2019s concizumab. Despite novel nonfactor hemophilia agents forecast to launch,\u00a0<abbr data-original-title=\"Decision Resources Group\" title=\"\">DRG<\/abbr>\u00a0expects the high demand for factor concentrates to persist. We anticipate the factor concentrate market will remain highly competitive, and pipeline agents are looking to further evolve this treatment approach.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How will physicians treating hemophilia A differentiate between the various emerging therapies, and which will gain the greatest market and patient share in an increasingly stringent regulatory environment?<\/li>\n<li>What clinical role will Hemlibra, fitusiran, and gene therapy play in the evolving hemophilia A treatment landscape?<\/li>\n<li>How will the management of patients with inhibitors change with the arrival of new treatment options? How will Hemlibra\u2019s head start on its competitors play out over the forecast period?<\/li>\n<li>What will be the market impact of gene therapies in hemophilia A?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>MARKETS COVERED<\/strong><\/p>\n<p>United States,\u00a0<abbr data-original-title=\"France, Germany, Italy, Spain, UK\" title=\"\">EU5<\/abbr>, Japan<\/p>\n<p><strong>PRIMARY RESEARCH INFO<\/strong><\/p>\n<p>20 country-specific interviews with thought-leading hematologists, specializing in hemophilia. Supported by survey data collected for this and other\u00a0<abbr data-original-title=\"Decision Resources Group\" title=\"\">DRG<\/abbr>\u00a0research.<\/p>\n<p><strong>KEY COMPANIES<\/strong><\/p>\n<p>Alnylam, Bayer, BioMarin, Bioverativ, Chugai, CSL Behring, Novo Nordisk, Octapharma, OPKO, Pfizer, Roche, Sanofi, Shire, Spark<\/p>\n<p><strong>KEY DRUGS<\/strong><\/p>\n<p>Advate, Adynovate\/Adynovi, Afstyla, BMN 270, concizumab, Eloctate\/Elocta, FEIBA, fitusiran,\u00a0<abbr data-original-title=\"factor VII (activated)\" title=\"\">FVIIa<\/abbr>\u00a0marzeptacog, Helixate, Hemlibra, Kogenate, Kovaltry,\u00a0N8-GP, Novoeight, NovoSeven, Nuwiq, OPK88005, ReFacto\/Xyntha, SPK-8011<\/p>\n","protected":false},"template":"","class_list":["post-390537","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hemophilia","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390537\/revisions"}],"predecessor-version":[{"id":576684,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390537\/revisions\/576684"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}